Merck raises annual profit outlook as Keytruda drives profit beat

Merck posted a higher-than-expected quarterly profit on Tuesday. The drugmaker also raised its full-year earnings forecast, driven by resilient demand for its blockbuster cancer therapy Keytruda during the Covid-19 pandemic.